Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

The FDA granted orphan designation to Sanofi ( SNY) US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Published first on TheFly – ...

Sanofi (NASDAQ:SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, its consumer healthcare business, to private equity firm CD&R. The terms of ...

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...

Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L’Oréal. This transaction is part of Sanofi’s share buyback program ...

In ulcerative colitis, duvakitug led to clinical remission in up to 48% of patients, with placebo-adjusted rates of 27% at the highest dose. In Crohn's disease, duvakitug achieved endoscopic ...

Sanofi delivered robust Q4 2024 results with strong growth across key products and new launches, including Dupixent and Beyfortus. The company’s strategic focus on R&D, pipeline productivity ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

Sanofi Consumer Healthcare India Q4 Results 2025:Sanofi Consumer Healthcare India declared their Q4 results on 20 Feb, 2025. The topline decreased by 20.53% year-over-year (YoY), with profit ...

Sanofi's rash of dealmaking has continued with a $2.5 billion tie-up with Chinese cancer immunotherapy biotech Adagene, focused on developing a new generation of safer antibody-based therapies.